Cibus, Inc. Class A Common Stock (CBUS) Stock
NASDAQ · CBUS
1.48
Fundamentals
Market cap
$116.17M
Price / Earnings ratio
-1.2x
Price / Sales ratio
26.4x
Price / Book ratio
7.7x
Return on assets
-31.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Zacks Investment Research
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
NeutralCBUSAugust 13, 2026
Zacks Investment ResearchNeutral
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
CBUS

MarketBeat
Cibus Q2 Earnings Call Highlights
NeutralCBUSAugust 13, 2026
MarketBeatNeutral
Cibus Q2 Earnings Call Highlights
CBUS

Zacks Investment Research
Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
NeutralCBUSMay 14, 2026
Zacks Investment ResearchNeutral
Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
CBUS

MarketBeat
Cibus Q1 Earnings Call Highlights
NeutralCBUSMay 14, 2026
MarketBeatNeutral
Cibus Q1 Earnings Call Highlights
CBUS
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy0
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
4M3M1M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
366M242M121M0
Revenue to Profit
2025$3.6M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-127.1M
Net incomeEarnings
No data available
% positive news of 7 articles
published over the past 14 days
Latest news

Zacks Investment Research
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
NeutralCBUSAugust 13, 2026
Zacks Investment ResearchNeutral
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates
CBUS

MarketBeat
Cibus Q2 Earnings Call Highlights
NeutralCBUSAugust 13, 2026
MarketBeatNeutral
Cibus Q2 Earnings Call Highlights
CBUS

Zacks Investment Research
Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
NeutralCBUSMay 14, 2026
Zacks Investment ResearchNeutral
Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates
CBUS

MarketBeat
Cibus Q1 Earnings Call Highlights
NeutralCBUSMay 14, 2026
MarketBeatNeutral
Cibus Q1 Earnings Call Highlights
CBUS

Zacks Investment Research
Cibus (CBUS) Upgraded to Buy: What Does It Mean for the Stock?
NeutralCBUSMay 6, 2026
Zacks Investment ResearchNeutral
Cibus (CBUS) Upgraded to Buy: What Does It Mean for the Stock?
CBUS

Zacks Investment Research
Cibus (CBUS) Reports Q4 Loss, Lags Revenue Estimates
NeutralCBUSMarch 17, 2026
Zacks Investment ResearchNeutral
Cibus (CBUS) Reports Q4 Loss, Lags Revenue Estimates
CBUS

Seeking Alpha
5 REITs That Are Overleveraged
NeutralCBUSOctober 3, 2023
Seeking AlphaNeutral
5 REITs That Are Overleveraged
CBUS
About Cibus, Inc. Class A Common Stock
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
SectorHealthcare
IndustryBiotechnology
Employees118
CEOMr. Craig Wichner
IPO DateJul 20, 2017
HeadquartersSan Diego, CA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Craig Wichner | Chief Executive Officer | 1970 |
| Dr. Peter R. Beetham B.Sc., Ph.D. | Co-Founder, President & COO | 1963 |
| Dr. Gregory F. Gocal Ph.D. | Co-Founder, Chief Scientific Officer & Executive VP | 1969 |
| Mr. Rory Balfour Riggs M.B.A. | Co-Founder & Director | 1953 |
| Mr. Jason Stokes Esq., J.D. | Chief Administrative Officer, General Counsel & Corporate Secretary | 1971 |
| Mr. Cornelis Broos M.Sc. | Chief Financial Officer | 1972 |
| Ms. Rosa Cheuk Kim J.D. | Senior Vice President of Legal | — |
| Dr. Noel Sauer Ph.D. | Senior Vice President of Research | 1967 |
Fundamentals
Valuation
Market cap$116.17M
Price-to-sales ratio26.36
Price-to-book value7.74
Price-earnings ratio-1.20
Return on Equity-226.00%
Return on Sales-1520.00%
Return on Assets-31.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.63
Income Statement
Average volume102,114
EBITDA$-59.68M
1 year high (52w)$4.19
1 year low (52w)$1.09
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
0 Wall Street Analyst Ratings
N/A
0% Buy
0% Hold
0% Sell
Target price
$0.00
Est return
0.00%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +13.2 | -46.6 | -27.5 | -0.7 | -6.8 | +35.9 | -14.3 | -2.6 |



